Share Price and Basic Stock Data
Last Updated: October 18, 2025, 8:03 pm
| PEG Ratio | 0.67 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Coral Laboratories Ltd operates in the pharmaceuticals sector, with a current price of ₹508 and a market capitalization of ₹181 Cr. The company reported a trailing twelve-month (TTM) sales figure of ₹78 Cr for the fiscal year ending March 2023, which rose to ₹84 Cr for the fiscal year ending March 2024, and is set to reach ₹115 Cr by March 2025. The quarterly sales data reflects a varied performance, with a peak of ₹32.23 Cr recorded in September 2024 and a low of ₹11.44 Cr in March 2023. Notably, the operating profit margin (OPM) was reported at 11.58%, indicating a stable profitability position. The company’s ability to maintain sales growth, despite fluctuations, suggests a potentially resilient business model, although the performance in certain quarters indicates vulnerability to market dynamics. Coral’s revenue growth trajectory is essential for sustaining investor interest and supporting its financial health.
Profitability and Efficiency Metrics
Coral Laboratories has shown a mixed performance in terms of profitability. The net profit for the fiscal year ending March 2023 was ₹6 Cr, which improved significantly to ₹16 Cr in March 2024 and is expected to reach ₹24 Cr by March 2025. The earnings per share (EPS) also reflect this positive trend, standing at ₹18.05 for FY 2023 and projected to rise to ₹67.63 in FY 2025. The company’s return on equity (ROE) is reported at 13.1%, while the return on capital employed (ROCE) stands at 17.4%, both of which are favorable compared to industry averages. Moreover, the interest coverage ratio (ICR) is remarkably high at 362.17x, indicating that the company generates substantial earnings relative to its interest obligations. However, the cash conversion cycle (CCC) of 129 days suggests potential inefficiencies in managing working capital, which could hinder liquidity if not addressed.
Balance Sheet Strength and Financial Ratios
The balance sheet of Coral Laboratories reveals a solid financial foundation, with total reserves amounting to ₹198 Cr against borrowings of only ₹4 Cr, resulting in a debt-to-equity ratio of 0.01x, which is significantly lower than the industry norm. This low leverage indicates a conservative approach to financing, enhancing the company’s financial stability. The company’s current ratio is reported at 7.07x, suggesting excellent liquidity and the ability to meet short-term obligations. Additionally, the price-to-book value (P/BV) ratio stands at 1.25x, which indicates that the market values the company at a premium compared to its book value, reflecting investor confidence. However, the company’s operating profit margin of 11.58% is lower than some of its peers, indicating potential areas for improvement in cost management and operational efficiency.
Shareholding Pattern and Investor Confidence
Coral Laboratories exhibits a stable shareholding structure, with promoters holding a significant 71.51% stake, indicating strong insider confidence in the company’s prospects. The public holds 28.50% of the shares, while foreign institutional investors (FIIs) have a negligible presence at 0.00%. This lack of foreign investment may suggest a need for improved visibility and attractiveness to institutional investors. The number of shareholders has fluctuated slightly, standing at 4,213 as of June 2025, highlighting a relatively stable investor base. The absence of dividends in recent years could be a concern for income-focused investors, but the reinvestment of profits into growth initiatives may be a strategic choice to enhance long-term value. Overall, the shareholding pattern reflects a strong commitment from promoters, which can be a positive signal for potential investors.
Outlook, Risks, and Final Insight
If Coral Laboratories can sustain its revenue growth momentum and improve its operational efficiency, it is likely to enhance its profitability further. The company faces risks such as fluctuating quarterly sales, which could impact cash flows, and the high cash conversion cycle that may strain liquidity. Additionally, the lack of foreign institutional investment could limit access to larger capital pools for expansion. However, the strong balance sheet and low debt levels provide a buffer against economic downturns. If the company successfully addresses its working capital management and leverages its strong financial ratios, it may position itself favorably for future growth and increased investor confidence. The focus on operational excellence and potential market expansion will be crucial in navigating the competitive pharmaceutical landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Coral Laboratories Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 148 Cr. | 117 | 247/84.3 | 33.6 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.96 Cr. | 2.07 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,702 Cr. | 432 | 440/192 | 105 | 22.8 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 36.4 Cr. | 49.0 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 30.0 Cr. | 20.4 | 29.1/17.0 | 31.2 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,828.94 Cr | 1,185.68 | 50.47 | 194.07 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 16.25 | 25.70 | 24.73 | 11.44 | 13.55 | 23.15 | 18.08 | 28.89 | 31.66 | 32.23 | 22.99 | 28.13 | 18.82 |
| Expenses | 15.52 | 21.39 | 23.88 | 13.52 | 11.81 | 17.00 | 15.98 | 22.64 | 20.92 | 25.72 | 16.67 | 25.44 | 16.64 |
| Operating Profit | 0.73 | 4.31 | 0.85 | -2.08 | 1.74 | 6.15 | 2.10 | 6.25 | 10.74 | 6.51 | 6.32 | 2.69 | 2.18 |
| OPM % | 4.49% | 16.77% | 3.44% | -18.18% | 12.84% | 26.57% | 11.62% | 21.63% | 33.92% | 20.20% | 27.49% | 9.56% | 11.58% |
| Other Income | 2.03 | 2.21 | 1.54 | 1.16 | 1.29 | 1.81 | 1.37 | 2.00 | 1.56 | 2.54 | 2.52 | 1.71 | 2.05 |
| Interest | 0.10 | 0.11 | 0.11 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.01 | 0.02 | 0.04 | 0.06 |
| Depreciation | 0.50 | 0.50 | 0.50 | 0.68 | 0.55 | 0.44 | 0.49 | 0.50 | 0.49 | 0.51 | 0.50 | 0.51 | 0.45 |
| Profit before tax | 2.16 | 5.91 | 1.78 | -1.62 | 2.48 | 7.52 | 2.98 | 7.75 | 11.78 | 8.53 | 8.32 | 3.85 | 3.72 |
| Tax % | 26.39% | 17.26% | 51.69% | -45.06% | 26.21% | 20.21% | 27.52% | 25.16% | 25.21% | 25.21% | 26.08% | 26.49% | 31.18% |
| Net Profit | 1.59 | 4.89 | 0.86 | -0.89 | 1.84 | 6.00 | 2.16 | 5.79 | 8.80 | 6.38 | 6.14 | 2.83 | 2.56 |
| EPS in Rs | 4.45 | 13.69 | 2.41 | -2.49 | 5.15 | 16.79 | 6.05 | 16.21 | 24.63 | 17.86 | 17.19 | 7.92 | 7.17 |
Last Updated: August 19, 2025, 8:45 pm
Below is a detailed analysis of the quarterly data for Coral Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 18.82 Cr.. The value appears to be declining and may need further review. It has decreased from 28.13 Cr. (Mar 2025) to 18.82 Cr., marking a decrease of 9.31 Cr..
- For Expenses, as of Jun 2025, the value is 16.64 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 25.44 Cr. (Mar 2025) to 16.64 Cr., marking a decrease of 8.80 Cr..
- For Operating Profit, as of Jun 2025, the value is 2.18 Cr.. The value appears to be declining and may need further review. It has decreased from 2.69 Cr. (Mar 2025) to 2.18 Cr., marking a decrease of 0.51 Cr..
- For OPM %, as of Jun 2025, the value is 11.58%. The value appears strong and on an upward trend. It has increased from 9.56% (Mar 2025) to 11.58%, marking an increase of 2.02%.
- For Other Income, as of Jun 2025, the value is 2.05 Cr.. The value appears strong and on an upward trend. It has increased from 1.71 Cr. (Mar 2025) to 2.05 Cr., marking an increase of 0.34 Cr..
- For Interest, as of Jun 2025, the value is 0.06 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.04 Cr. (Mar 2025) to 0.06 Cr., marking an increase of 0.02 Cr..
- For Depreciation, as of Jun 2025, the value is 0.45 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.51 Cr. (Mar 2025) to 0.45 Cr., marking a decrease of 0.06 Cr..
- For Profit before tax, as of Jun 2025, the value is 3.72 Cr.. The value appears to be declining and may need further review. It has decreased from 3.85 Cr. (Mar 2025) to 3.72 Cr., marking a decrease of 0.13 Cr..
- For Tax %, as of Jun 2025, the value is 31.18%. The value appears to be increasing, which may not be favorable. It has increased from 26.49% (Mar 2025) to 31.18%, marking an increase of 4.69%.
- For Net Profit, as of Jun 2025, the value is 2.56 Cr.. The value appears to be declining and may need further review. It has decreased from 2.83 Cr. (Mar 2025) to 2.56 Cr., marking a decrease of 0.27 Cr..
- For EPS in Rs, as of Jun 2025, the value is 7.17. The value appears to be declining and may need further review. It has decreased from 7.92 (Mar 2025) to 7.17, marking a decrease of 0.75.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:35 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 51 | 59 | 77 | 95 | 92 | 91 | 71 | 97 | 76 | 78 | 84 | 115 | 102 |
| Expenses | 41 | 47 | 60 | 72 | 77 | 79 | 65 | 81 | 67 | 74 | 67 | 89 | 84 |
| Operating Profit | 10 | 12 | 16 | 23 | 15 | 12 | 5 | 16 | 8 | 4 | 16 | 26 | 18 |
| OPM % | 20% | 21% | 21% | 24% | 17% | 14% | 8% | 16% | 11% | 5% | 19% | 23% | 17% |
| Other Income | 1 | 3 | 3 | 3 | 4 | 5 | 6 | 4 | 6 | 7 | 6 | 8 | 9 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 10 | 12 | 17 | 25 | 18 | 16 | 9 | 18 | 12 | 8 | 21 | 32 | 24 |
| Tax % | 21% | 22% | 29% | 34% | 31% | 34% | 22% | 23% | 24% | 22% | 24% | 26% | |
| Net Profit | 8 | 10 | 12 | 16 | 12 | 10 | 7 | 14 | 9 | 6 | 16 | 24 | 18 |
| EPS in Rs | 22.03 | 26.79 | 34.71 | 45.63 | 34.85 | 28.61 | 19.96 | 37.93 | 25.33 | 18.05 | 44.20 | 67.63 | 50.14 |
| Dividend Payout % | 9% | 9% | 9% | 11% | 6% | 7% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 25.00% | 20.00% | 33.33% | -25.00% | -16.67% | -30.00% | 100.00% | -35.71% | -33.33% | 166.67% | 50.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -5.00% | 13.33% | -58.33% | 8.33% | -13.33% | 130.00% | -135.71% | 2.38% | 200.00% | -116.67% |
Coral Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 10% |
| 3 Years: | 15% |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 28% |
| 3 Years: | 44% |
| TTM: | -19% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 9% |
| 3 Years: | 21% |
| 1 Year: | -48% |
| Return on Equity | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 9% |
| 3 Years: | 9% |
| Last Year: | 13% |
Last Updated: September 5, 2025, 3:01 pm
Balance Sheet
Last Updated: July 25, 2025, 1:31 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Reserves | 47 | 56 | 67 | 106 | 113 | 110 | 112 | 133 | 152 | 151 | 174 | 198 |
| Borrowings | 0 | 1 | 0 | 2 | 2 | 1 | 6 | 6 | 6 | 0 | 0 | 4 |
| Other Liabilities | 10 | 12 | 19 | 20 | 22 | 21 | 23 | 25 | 28 | 20 | 28 | 25 |
| Total Liabilities | 60 | 72 | 89 | 131 | 140 | 136 | 144 | 168 | 190 | 174 | 206 | 229 |
| Fixed Assets | 20 | 19 | 18 | 18 | 22 | 23 | 23 | 21 | 24 | 25 | 24 | 23 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 |
| Investments | 1 | 1 | 5 | 39 | 45 | 28 | 25 | 33 | 46 | 41 | 50 | 52 |
| Other Assets | 40 | 52 | 67 | 74 | 73 | 84 | 97 | 112 | 118 | 108 | 132 | 152 |
| Total Assets | 60 | 72 | 89 | 131 | 140 | 136 | 144 | 168 | 190 | 174 | 206 | 229 |
Below is a detailed analysis of the balance sheet data for Coral Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 4.00 Cr..
- For Reserves, as of Mar 2025, the value is 198.00 Cr.. The value appears strong and on an upward trend. It has increased from 174.00 Cr. (Mar 2024) to 198.00 Cr., marking an increase of 24.00 Cr..
- For Borrowings, as of Mar 2025, the value is 4.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 0.00 Cr. (Mar 2024) to 4.00 Cr., marking an increase of 4.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 25.00 Cr.. The value appears to be improving (decreasing). It has decreased from 28.00 Cr. (Mar 2024) to 25.00 Cr., marking a decrease of 3.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 229.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 206.00 Cr. (Mar 2024) to 229.00 Cr., marking an increase of 23.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 23.00 Cr.. The value appears to be declining and may need further review. It has decreased from 24.00 Cr. (Mar 2024) to 23.00 Cr., marking a decrease of 1.00 Cr..
- For CWIP, as of Mar 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2024) to 2.00 Cr., marking an increase of 2.00 Cr..
- For Investments, as of Mar 2025, the value is 52.00 Cr.. The value appears strong and on an upward trend. It has increased from 50.00 Cr. (Mar 2024) to 52.00 Cr., marking an increase of 2.00 Cr..
- For Other Assets, as of Mar 2025, the value is 152.00 Cr.. The value appears strong and on an upward trend. It has increased from 132.00 Cr. (Mar 2024) to 152.00 Cr., marking an increase of 20.00 Cr..
- For Total Assets, as of Mar 2025, the value is 229.00 Cr.. The value appears strong and on an upward trend. It has increased from 206.00 Cr. (Mar 2024) to 229.00 Cr., marking an increase of 23.00 Cr..
Notably, the Reserves (198.00 Cr.) exceed the Borrowings (4.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 10.00 | 11.00 | 16.00 | 21.00 | 13.00 | 11.00 | -1.00 | 10.00 | 2.00 | 4.00 | 16.00 | 22.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 109 | 152 | 132 | 117 | 125 | 122 | 178 | 148 | 184 | 109 | 123 | 107 |
| Inventory Days | 97 | 110 | 110 | 155 | 120 | 116 | 176 | 158 | 169 | 100 | 149 | 68 |
| Days Payable | 61 | 66 | 80 | 75 | 87 | 91 | 129 | 108 | 81 | 34 | 130 | 46 |
| Cash Conversion Cycle | 145 | 196 | 162 | 197 | 157 | 146 | 225 | 198 | 272 | 176 | 142 | 129 |
| Working Capital Days | 158 | 194 | 179 | 164 | 161 | 171 | 241 | 178 | 222 | 221 | 183 | 140 |
| ROCE % | 21% | 22% | 27% | 28% | 16% | 13% | 8% | 13% | 7% | 5% | 13% | 17% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 67.61 | 44.19 | 18.04 | 25.32 | 37.94 |
| Diluted EPS (Rs.) | 67.61 | 44.19 | 18.04 | 25.32 | 37.94 |
| Cash EPS (Rs.) | 73.24 | 49.72 | 24.14 | 30.89 | 43.49 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 563.19 | 496.83 | 433.29 | 436.81 | 382.48 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 563.19 | 496.83 | 433.29 | 436.81 | 382.48 |
| Dividend / Share (Rs.) | 1.50 | 2.00 | 0.00 | 0.00 | 0.00 |
| Revenue From Operations / Share (Rs.) | 321.91 | 234.17 | 218.66 | 211.64 | 270.30 |
| PBDIT / Share (Rs.) | 98.94 | 64.02 | 29.97 | 36.47 | 54.91 |
| PBIT / Share (Rs.) | 93.31 | 58.49 | 23.87 | 30.89 | 49.37 |
| PBT / Share (Rs.) | 90.89 | 58.03 | 23.02 | 33.19 | 49.25 |
| Net Profit / Share (Rs.) | 67.61 | 44.19 | 18.04 | 25.32 | 37.94 |
| PBDIT Margin (%) | 30.73 | 27.33 | 13.70 | 17.23 | 20.31 |
| PBIT Margin (%) | 28.98 | 24.97 | 10.91 | 14.59 | 18.26 |
| PBT Margin (%) | 28.23 | 24.78 | 10.53 | 15.67 | 18.21 |
| Net Profit Margin (%) | 21.00 | 18.87 | 8.25 | 11.96 | 14.03 |
| Return on Networth / Equity (%) | 12.00 | 8.89 | 4.16 | 5.79 | 9.91 |
| Return on Capital Employeed (%) | 16.30 | 11.55 | 5.24 | 6.71 | 12.61 |
| Return On Assets (%) | 10.52 | 7.67 | 3.69 | 4.76 | 8.09 |
| Total Debt / Equity (X) | 0.01 | 0.00 | 0.00 | 0.03 | 0.04 |
| Asset Turnover Ratio (%) | 0.52 | 0.44 | 0.42 | 0.42 | 0.61 |
| Current Ratio (X) | 7.07 | 6.18 | 10.42 | 5.13 | 3.99 |
| Quick Ratio (X) | 6.68 | 5.57 | 9.36 | 4.41 | 3.21 |
| Inventory Turnover Ratio (X) | 3.85 | 2.87 | 2.68 | 1.92 | 2.39 |
| Interest Coverage Ratio (X) | 362.17 | 114356.50 | 31.63 | 92.33 | 461.63 |
| Interest Coverage Ratio (Post Tax) (X) | 256.38 | 79763.50 | 19.93 | 58.31 | 319.93 |
| Enterprise Value (Cr.) | 174.27 | 71.40 | 41.37 | 59.77 | 86.55 |
| EV / Net Operating Revenue (X) | 1.52 | 0.85 | 0.52 | 0.79 | 0.89 |
| EV / EBITDA (X) | 4.93 | 3.12 | 3.86 | 4.59 | 4.41 |
| MarketCap / Net Operating Revenue (X) | 2.18 | 1.59 | 1.05 | 1.21 | 1.19 |
| Price / BV (X) | 1.25 | 0.74 | 0.52 | 0.58 | 0.84 |
| Price / Net Operating Revenue (X) | 2.18 | 1.59 | 1.05 | 1.21 | 1.19 |
| EarningsYield | 0.09 | 0.11 | 0.07 | 0.09 | 0.11 |
After reviewing the key financial ratios for Coral Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 67.61. This value is within the healthy range. It has increased from 44.19 (Mar 24) to 67.61, marking an increase of 23.42.
- For Diluted EPS (Rs.), as of Mar 25, the value is 67.61. This value is within the healthy range. It has increased from 44.19 (Mar 24) to 67.61, marking an increase of 23.42.
- For Cash EPS (Rs.), as of Mar 25, the value is 73.24. This value is within the healthy range. It has increased from 49.72 (Mar 24) to 73.24, marking an increase of 23.52.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 563.19. It has increased from 496.83 (Mar 24) to 563.19, marking an increase of 66.36.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 563.19. It has increased from 496.83 (Mar 24) to 563.19, marking an increase of 66.36.
- For Dividend / Share (Rs.), as of Mar 25, the value is 1.50. This value is within the healthy range. It has decreased from 2.00 (Mar 24) to 1.50, marking a decrease of 0.50.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 321.91. It has increased from 234.17 (Mar 24) to 321.91, marking an increase of 87.74.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 98.94. This value is within the healthy range. It has increased from 64.02 (Mar 24) to 98.94, marking an increase of 34.92.
- For PBIT / Share (Rs.), as of Mar 25, the value is 93.31. This value is within the healthy range. It has increased from 58.49 (Mar 24) to 93.31, marking an increase of 34.82.
- For PBT / Share (Rs.), as of Mar 25, the value is 90.89. This value is within the healthy range. It has increased from 58.03 (Mar 24) to 90.89, marking an increase of 32.86.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 67.61. This value is within the healthy range. It has increased from 44.19 (Mar 24) to 67.61, marking an increase of 23.42.
- For PBDIT Margin (%), as of Mar 25, the value is 30.73. This value is within the healthy range. It has increased from 27.33 (Mar 24) to 30.73, marking an increase of 3.40.
- For PBIT Margin (%), as of Mar 25, the value is 28.98. This value exceeds the healthy maximum of 20. It has increased from 24.97 (Mar 24) to 28.98, marking an increase of 4.01.
- For PBT Margin (%), as of Mar 25, the value is 28.23. This value is within the healthy range. It has increased from 24.78 (Mar 24) to 28.23, marking an increase of 3.45.
- For Net Profit Margin (%), as of Mar 25, the value is 21.00. This value exceeds the healthy maximum of 10. It has increased from 18.87 (Mar 24) to 21.00, marking an increase of 2.13.
- For Return on Networth / Equity (%), as of Mar 25, the value is 12.00. This value is below the healthy minimum of 15. It has increased from 8.89 (Mar 24) to 12.00, marking an increase of 3.11.
- For Return on Capital Employeed (%), as of Mar 25, the value is 16.30. This value is within the healthy range. It has increased from 11.55 (Mar 24) to 16.30, marking an increase of 4.75.
- For Return On Assets (%), as of Mar 25, the value is 10.52. This value is within the healthy range. It has increased from 7.67 (Mar 24) to 10.52, marking an increase of 2.85.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.52. It has increased from 0.44 (Mar 24) to 0.52, marking an increase of 0.08.
- For Current Ratio (X), as of Mar 25, the value is 7.07. This value exceeds the healthy maximum of 3. It has increased from 6.18 (Mar 24) to 7.07, marking an increase of 0.89.
- For Quick Ratio (X), as of Mar 25, the value is 6.68. This value exceeds the healthy maximum of 2. It has increased from 5.57 (Mar 24) to 6.68, marking an increase of 1.11.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.85. This value is below the healthy minimum of 4. It has increased from 2.87 (Mar 24) to 3.85, marking an increase of 0.98.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 362.17. This value is within the healthy range. It has decreased from 114,356.50 (Mar 24) to 362.17, marking a decrease of 113,994.33.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 256.38. This value is within the healthy range. It has decreased from 79,763.50 (Mar 24) to 256.38, marking a decrease of 79,507.12.
- For Enterprise Value (Cr.), as of Mar 25, the value is 174.27. It has increased from 71.40 (Mar 24) to 174.27, marking an increase of 102.87.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.52. This value is within the healthy range. It has increased from 0.85 (Mar 24) to 1.52, marking an increase of 0.67.
- For EV / EBITDA (X), as of Mar 25, the value is 4.93. This value is below the healthy minimum of 5. It has increased from 3.12 (Mar 24) to 4.93, marking an increase of 1.81.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.18. This value is within the healthy range. It has increased from 1.59 (Mar 24) to 2.18, marking an increase of 0.59.
- For Price / BV (X), as of Mar 25, the value is 1.25. This value is within the healthy range. It has increased from 0.74 (Mar 24) to 1.25, marking an increase of 0.51.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.18. This value is within the healthy range. It has increased from 1.59 (Mar 24) to 2.18, marking an increase of 0.59.
- For EarningsYield, as of Mar 25, the value is 0.09. This value is below the healthy minimum of 5. It has decreased from 0.11 (Mar 24) to 0.09, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Coral Laboratories Ltd:
- Net Profit Margin: 21%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 16.3% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 256.38
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 6.68
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 9.83 (Industry average Stock P/E: 50.47)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 21%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 3B, Patanwala Compound, Mumbai Maharashtra 400086 | cs@corallab.com http://www.corallab.com |
| Management | |
|---|---|
| Name | Position Held |
| Mrs. Sushma Kadkade | Director & CFO |
| Ms. Pooja Hindia | Independent Director |
| Dr. Saurabh Shah | Independent Director |
| Mr. Malay Doshi | Independent Director |
| Mr. Rajendrasinh Rana | Director |
| Mr. Girish M Dhameja | Whole Time Director |
FAQ
What is the intrinsic value of Coral Laboratories Ltd?
Coral Laboratories Ltd's intrinsic value (as of 19 October 2025) is 581.68 which is 14.50% higher the current market price of 508.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 182 Cr. market cap, FY2025-2026 high/low of 896/443, reserves of ₹198 Cr, and liabilities of 229 Cr.
What is the Market Cap of Coral Laboratories Ltd?
The Market Cap of Coral Laboratories Ltd is 182 Cr..
What is the current Stock Price of Coral Laboratories Ltd as on 19 October 2025?
The current stock price of Coral Laboratories Ltd as on 19 October 2025 is 508.
What is the High / Low of Coral Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Coral Laboratories Ltd stocks is 896/443.
What is the Stock P/E of Coral Laboratories Ltd?
The Stock P/E of Coral Laboratories Ltd is 9.83.
What is the Book Value of Coral Laboratories Ltd?
The Book Value of Coral Laboratories Ltd is 563.
What is the Dividend Yield of Coral Laboratories Ltd?
The Dividend Yield of Coral Laboratories Ltd is 0.29 %.
What is the ROCE of Coral Laboratories Ltd?
The ROCE of Coral Laboratories Ltd is 17.4 %.
What is the ROE of Coral Laboratories Ltd?
The ROE of Coral Laboratories Ltd is 13.1 %.
What is the Face Value of Coral Laboratories Ltd?
The Face Value of Coral Laboratories Ltd is 10.0.